Psoriasis Comorbidities in Childhood

Psoriasis is multifactorial systemic disease characterized by excessive hyperkeratosis due to impaired keratinocytes proliferation and differentiation. This disease often manifests in childhood and it is usually associated with the development of comorbid conditions some of which are combined by the term «psoriatic march» (obesity, metabolic syndrome, etc.). The course of psoriasis and related comorbidities in children has several specific features that determine topicality of studying all the aspects of clinical diagnosis and prevention in childhood. The article summarizes recent ideas on the prevalence, pathogenesis features and early diagnosis of comorbid diseases in children with psoriasis.

1. Psoriaz u detei: klinicheskie rekomendatsii. Soyuz pediatrov Rossii; 2016. (In Russ). Av. at: https://medi.ru/klinicheskie-rekomendatsii/psoriaz-u-detej_14213. Link active on 22.10.2020.

2. Wong Y, Nakamizo S, Tan KJ, Kabashima K. An Update on the Role of Adipose Tissues in Psoriasis. Front Immunol. 2019;10:1507. doi: 10.3389/fimmu.2019.01507.

3. Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017;18(6):797–811. doi: 10.1007/s40257-017-0294-9.

4. Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: 10.1111/pde.13772.

5. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: A systematic review and metaanalysis of observational studies. Nutr Diabetes. 2012;2:e54. doi: 10.1038/nutd.2012.26.

6. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251. doi: 10.1056/nejmoa066886.

7. Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis. Br J Dermatol. 2009;161(2):484–486. doi: 10.1111/j.1365-2133.2009.09276.x.

8. Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–176. doi: 10.1001/jamadermatol.2013.1078.

9. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013; 339(6116):172–177. doi: 10.1126/science.1230721.

10. Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection. Immunity. 2017;47(6):1154–1168. doi: 10.1016%2Fj.immuni.2017.11.009.

11. Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+ Sca-1+ lymphoid cells. Nature. 2010;463(7280):540–544. doi: 10.1038/nature08636.

12. Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56(11):1103–1118. doi: 10.1111/ijd.13699.

13. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–919. doi: 10.1016/j.jaci.2005.02.023.

14. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010; 24(12):1386–1394. doi: 10.1111/j.1468-3083.2010.03647.x

15. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130(7):1785–1796. doi: 10.1038/jid.2010.103.

16. Ommen P, Stjernholm T, Kragstrup T, et al. The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast. Br J Dermatol. 2016;174(1):187–90. doi: 10.1111/bjd.13969.

17. Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092–1101. doi: 10.1016/j.bbrc.2005.06.202.

18. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9): 5789–5795. doi: 10.4049/jimmunol.174.9.5789.

19. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79. doi: 10.1006/bbrc.1999.0255.

20. Shibata S, Tada Y, Hau CS, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from -T cells. Nat Commun. 2015;6:7687. doi: 10.1038/ncomms8687.

21. Endo Y, Asou HK, Matsugae N, et al. Obesity drives Th17 cell differentiation by inducing the lipid metabolic kinase, ACC1. Cell Rep. 2015;12(6):1042–1055. doi: 10.1016/j.celrep.2015.07.014.

22. Kanemaru K, Matsuyuki A, Nakamura Y, Fukami K. Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin- 17 and interleukin-22 production in mice. Exp Dermatol. 2015;24(6):436–442. doi: 10.1111/exd.12691.

23. Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal T cells number: A prospective case series study. Br J Dermatol. 2014;171(1): 155–161. doi: 10.1111/bjd.12886.

24. Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38(1):86–88. doi: 10.1016/j.diabet.2011.11.004.

25. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829. doi: 10.1016/j.jaad.2006.08.040.

26. Badaoui A, Tounian P, Mahe E. Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review. Arch Pediatr. 2019;26(2):86–94. doi: 10.1016/j.arcped.2018.12.005.

27. Osier E, Wang AS, Tollefson MM, Cordoro KM. Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol. 2017; 153(7):698–704. doi: 10.1001/jamadermatol.2017.0499.

28. Rekomendatsii po vedeniyu bol’nykh s metabolicheskim sindromom: klinicheskie rekomendatsii. Soyuz pediatrov Rossii; 2013. (In Russ). Av. at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjF28KP8MfsAhXpxIsKHfKSAwkQFjAAegQIBBAC&url=http%3A%2F%2Fwww.gipertonik.ru%2Ffiles%2Frecommendation%2FRecommendations_metabolic_syndrome.doc&usg=AOvVaw0OlaDnVqEqE_s6p37JaUFm. Link active on 22.10.2020.

29. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi: 10.1016/j.jaad.2012.08.015.

30. Goldminz AM, Buzney CD, Kim N, et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol. 2013;30(6):700–705. doi: 10.1111/pde.12218.

31. Tom WL, Playford MP, Admani S, et al. Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile. J Invest Dermatol. 2016;136(1):67–73. doi: 10.1038/jid.2015.385.

32. Al Mutairi N, Alrqobah D, Haji Hussain N. Prevalence of metabolic syndrome in children with moderate to severe psoriasis treated with TNF inhibitors in comparison to conventional agents. Dermatol Ther. 2018;31(1). doi: 10.1111/dth.12566.

33. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. doi: 10.1016/s0140-6736(05)66378-7.

34. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi: 10.1007/s00403-006-0703-z.

35. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi: 10.1111/j.1600-0625.2011.01261.x.

36. Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148(9):995–1000. doi: 10.1001/archdermatol.2012.1401.

37. Li W, Han J, Hu FB, et al. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol. 2012;132(2):291–298. doi: 10.1038/jid.2011.319.

38. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): 1735–1741. doi: 10.1001/jama.296.14.1735.

39. Mehta NN, Li K, Szapary P, et al. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med. 2013;11:194. doi: 10.1186/1479-5876-11-194.

40. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012;147(2):179–187.

41. Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1- dependent monocyte adhesion and transendothelial migration. Circ Res. 2011;108(3):335–343. doi: 10.1161/circresaha.110.237420.

42. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of plateletderived microparticles and soluble P-selectin. J Am Acad Dermatol. 2010;62(4):621–626. doi: 10.1016/j.jaad.2009.06.053.

43. Turonova L, Kubejova K, Vorcakova K, et al. Endothelial Dysfunction in Children with Juvenile Psoriatic Arthritis. Acta Medica (Hradec Kralove). 2018;61(3):79–85. doi: 10.14712/18059694.2018.122.

44. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Am Acad Dermatol. 2020;82(1):161–201. doi: 10.1016/j.jaad.2019.08.049.

45. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218(2):110–113. doi: 10.1159/000182256.

46. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271–276. doi: 10.1111/j.1365-2133.2006.07562.x.

47. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi: 10.1111/jdv.13854.

48. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568. doi: 10.1016/j.rdc.2015.07.001.

49. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–443. doi: 10.1097/bor.0b013e328348b278.

50. Tosato F, Bucciol G, Pantano G, et al. Lymphocytes subsets reference values in childhood. Cytometry A. 2015;87(1):81–85. doi: https://doi.org/10.1002/cyto.a.22520

51. Decker ML, Gotta V, Wellmann S, Ritz N. Cytokine profiling in healthy children shows association of age with cytokine concentrations. Sci Rep. 2017;7(1):17842. doi: 10.1038/s41598-017-17865-2.

52. Yatsunenko T, Rey FE, Manary MJ, Trehan I. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402): 222–227. doi: 10.1038/nature11053.

53. Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–197. doi: 10.3899/jrheum.180168.

54. Korotaeva TV, Korsakova YuL, Loginova EYu, et al. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(2):22–35. (In Russ). doi: 10.14412/1996-7012-2018-2-22-35.

55. Helliwell PS. Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting. J Rheumatol. 201;38(3):551–552. doi: 10.3899/jrheum.101119.

56. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an exis ting screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009; 27(3):469–474.

57. Niccoli L, Nannini C, Cassara E, et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis. 2012;15(4):414–418. doi: 10.1111/j.1756-185x.2012.01736.x.

58. Centers for Disease Control and Prevention. What is IBD? Available online: https://www.cdc.gov/ibd/what-is-IBD.htm. Accessed on 25 May, 2020.

59. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–764. doi: 10.1016/j.jhep.2009.04.020.

60. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40(7):722–727. doi: 10.1111/ced.12672.

61. Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657.e1–2. doi: 10.1016/j.jaad.2011.11.948.

62. Salek MS, Jung S, Brincat-Ruffini LA, et al. Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995–2012. Br J Dermatol. 2013;169(4):734–759. doi: 10.1046/j.1525-1470.2002.00026.x.